Ixekizumab-induced Interstitial Lung Disease

Am J Ther. 2024 May-Jun;31(3):e315-e318. doi: 10.1097/MJT.0000000000001628. Epub 2023 Jul 7.

Authors

Alaaeldin Ahmed^{1

2}, Prateek Khanna³, Omar Al Omari^{1

2}, Chinmay Jani^{1

2}, Dipesh Patel^{2

4}, Harpreet Singh⁵, Robert Schiffman^{1

2

6}

Affiliations

¹ Department of Medicine, Mount Auburn Hospital, Cambridge, MA.
² Harvard Medical School, Boston, MA.
³ Division of Hematology and Oncology, Department of Medicine, St Elizabeth Medical Center, Boston, MA.
⁴ Department of Radiology, Mount Auburn Hospital, Cambridge, MA.
⁵ Department of Pulmonary and Critical Care, Medical College of Wisconsin, Milwaukee, WI; and.
⁶ Division of Pulmonary and Critical Care, Mount Auburn Hospital, Cambridge, MA.

PMID: 37418343
DOI: 10.1097/MJT.0000000000001628

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Dermatologic Agents / adverse effects
Female
Humans
Lung Diseases, Interstitial* / chemically induced
Lung Diseases, Interstitial* / drug therapy
Male
Middle Aged
Psoriasis / chemically induced
Psoriasis / drug therapy
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal, Humanized
ixekizumab
Dermatologic Agents